Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

ATAI

ATAI Life Sciences N.V.

Apr 18 • 04:00PM ET

1.91

Dollar change -0.07
Percentage change -3.54	%

Healthcare • Biotechnology • Germany • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: IBB VHT PSIL AVSC BIB IBBQ GWX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.26	Insider Own	30.44%	Shs Outstand	166.03M	Perf Week	-22.67%
Market Cap	317.12M	Forward P/E	-	EPS next Y	-0.77	Insider Trans	-0.21%	Shs Float	115.49M	Perf Month	14.37%
Income	-40.23M	PEG	-	EPS next Q	-0.18	Inst Own	8.25%	Short Float	4.81%	Perf Quarter	7.91%
Sales	0.31M	P/S	1022.96	EPS this Y	-210.00%	Inst Trans	11.11%	Short Ratio	3.41	Perf Half Y	44.70%
Book/sh	1.46	P/B	1.31	EPS next Y	0.65%	ROA	-13.43%	Short Interest	5.55M	Perf Year	-4.98%
Cash/sh	0.93	P/C	2.06	EPS next 5Y	-	ROE	-15.97%	52W Range	1.02 - 2.85	Perf YTD	35.46%
Dividend Est.	-	P/FCF	-	EPS past 5Y	44.19%	ROI	-15.52%	52W High	-32.98%	Beta	0.92
Dividend TTM	-	Quick Ratio	9.22	Sales past 5Y	-16.02%	Gross Margin	-71.02%	52W Low	86.34%	ATR (14)	0.21
Dividend Ex-Date	-	Current Ratio	9.22	EPS Y/Y TTM	73.83%	Oper. Margin	-39927.07%	RSI (14)	44.40	Volatility	11.18% 10.79%
Employees	83	Debt/Eq	0.07	Sales Y/Y TTM	35.34%	Profit Margin	-12810.51%	Recom	1.00	Target Price	9.50
Option/Short	Yes / Yes	LT Debt/Eq	0.07	EPS Q/Q	59.38%	Payout	-	Rel Volume	0.62	Prev Close	1.98
Sales Surprise	-96.80%	EPS Surprise	20.90%	Sales Q/Q	-52.63%	Earnings	Mar 28 BMO	Avg Volume	1.63M	Price	1.91
SMA20	-8.22%	SMA50	-2.59%	SMA200	16.48%	Trades		Volume	1,016,014	Change	-3.54%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-03-24	Upgrade	Maxim Group	Hold → Buy	$6
Nov-01-22	Initiated	Loop Capital	Buy	$18
Nov-30-21	Initiated	Maxim Group	Buy	$25
Nov-11-21	Initiated	ROTH Capital	Buy	$32
Oct-18-21	Initiated	H.C. Wainwright	Buy	$40
Sep-01-21	Initiated	Jefferies	Buy	$27
Jul-13-21	Initiated	RBC Capital Mkts	Sector Perform	$19
Jul-13-21	Initiated	Credit Suisse	Outperform	$25
Jul-13-21	Initiated	Cowen	Outperform
Jul-13-21	Initiated	Citigroup	Buy	$26
Jul-13-21	Initiated	Cantor Fitzgerald	Buy	$45
Jul-13-21	Initiated	Canaccord Genuity	Buy	$28
Jul-13-21	Initiated	Berenberg	Buy	$35
Jul-08-21	Initiated	Aegis Capital	Buy	$26

Show Previous Ratings

Apr-17-24 07:00AM	atai Life Sciences Announces the Publication of Beckley Psytech's Phase 1 Study of BPL-003 in the Journal of Psychopharmacology (GlobeNewswire) -7.91%
Mar-28-24 07:00AM	atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights (GlobeNewswire) +10.06%
Mar-27-24 07:00AM	atai Life Sciences Announces Positive Initial Results from Beckley Psytech's Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression (GlobeNewswire)
Mar-19-24 08:00AM	The Next Great Biotech Boom Has Arrived (PR Newswire)
Mar-12-24 12:35PM	atai Life Sciences advances VLS-01 for treatment-resistant depression (News Direct) -5.45%
08:00AM	Loading…
Mar-04-24 08:00AM	atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01 (GlobeNewswire)
Feb-28-24 05:00PM	atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-06-24 05:00PM	atai Life Sciences Appoints Anne Johnson as Chief Financial Officer (GlobeNewswire)
Jan-24-24 09:00AM	How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition (PR Newswire)
Jan-07-24 10:15PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Jan-05-24 08:54AM	Ecstasy-for-Medicine Advocate Raises $100 Million (The Wall Street Journal)
08:00AM	Legalization Advocate MAPS Raises Money for Pharmaceutical Psychedelics (The Wall Street Journal)
Jan-04-24 07:00AM	atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics (GlobeNewswire) +14.67%
Jan-02-24 08:00AM	atai Life Sciences Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01 (R-MDMA) (GlobeNewswire) +19.86%
Nov-14-23 07:03AM	atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights (GlobeNewswire) +9.13%
05:06PM	Loading…
Oct-15-23 05:06PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Oct-10-23 08:00AM	ATAI LIFE SCIENCES ANNOUNCES FILING OF EARLY WARNING REPORT (PR Newswire)
Oct-06-23 04:05PM	atai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit (GlobeNewswire) -8.55%
Oct-02-23 04:13PM	atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants (GlobeNewswire)
Sep-14-23 11:02PM	Insider Buying: Florian Brand Acquires 40,000 Shares of ATAI Life Sciences NV (GuruFocus.com)
08:02AM	atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
Sep-06-23 04:01PM	atai Life Sciences to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-10-23 06:59AM	atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine) (GlobeNewswire)
Aug-08-23 04:02PM	atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine) (GlobeNewswire)
Jun-28-23 09:37AM	Ecstasy-for-Medicine Advocate Seeks Cash Lifeline (The Wall Street Journal) +7.89%
Jun-01-23 09:10AM	Atossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial Officer (GlobeNewswire)
06:59AM	atai Life Sciences to Participate in Upcoming June Investor Conferences (GlobeNewswire)
May-11-23 06:59AM	atai Life Sciences Reports First Quarter 2023 Financial Results and Announces Pipeline Highlights and Updates (GlobeNewswire)
May-02-23 05:20PM	atai Life Sciences to Participate in Upcoming May Investor Conference (GlobeNewswire)
Apr-28-23 06:59AM	atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late Breaking Poster Presentation at the 2023 SOBP Annual Meeting (GlobeNewswire)
06:59AM	Loading…
Apr-13-23 06:59AM	atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine) (GlobeNewswire) +9.89%
Apr-03-23 07:00AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Mar-31-23 06:36AM	Daily Vickers Top Buyers & Sellers for 03/31/2023 (Argus Research) +13.12%
Mar-24-23 06:59AM	atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights (GlobeNewswire) +5.04%
Mar-06-23 07:00AM	atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates (GlobeNewswire)
Mar-01-23 04:01PM	atai Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Jan-19-23 01:24PM	This Analyst Still Has Confidence In Atai Life Sciences' Pipeline Despite Recent Setbacks (Benzinga)
Jan-17-23 05:00AM	Trippy Trading: Top Psychedelic Stocks For 2023 (News Direct) +7.78%
Jan-09-23 07:00AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive) -9.34%
06:59AM	atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917 (GlobeNewswire)
Jan-06-23 10:38AM	Atai Life Sciences' Depression Candidate Faces Trial Setback, Shares Nosedive (Benzinga) -30.80%
07:00AM	atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression (GlobeNewswire)
Dec-23-22 06:59AM	atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101 (GlobeNewswire) -12.17%
Dec-19-22 06:59AM	atai Life Sciences Initiates Phase 2b proof-of-concept trial of RL-007 for Cognitive Impairment Associated with Schizophrenia (GlobeNewswire)
Dec-16-22 10:00AM	The atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort at Massachusetts General Hospital (GlobeNewswire)
Dec-01-22 07:39PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive) -5.38%
Nov-29-22 06:59AM	atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil V. Kirpekar as Chief Business Officer (GlobeNewswire)
Nov-17-22 07:00AM	atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity Biomarkers in Treatment-Resistant Depression Patients Undergoing Ketamine Treatment (GlobeNewswire)
Nov-10-22 06:59AM	atai Life Sciences Reports Third Quarter 2022 Financial Results and Business Update (GlobeNewswire) +7.72%
Nov-04-22 09:35AM	Women in Psychedelics Announces atai as Platinum Sponsors (Business Wire)
Nov-01-22 12:00PM	atai Life Sciences to Participate in November Investor Events & Healthcare Conferences (GlobeNewswire) +14.58%
07:00AM	atai Life Sciences to Announce Third Quarter 2022 Financial Results and Business Update (GlobeNewswire)
Oct-25-22 07:03AM	atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression (GlobeNewswire)
Oct-20-22 06:59AM	atai Life Sciences Announces R&D Day Agenda (GlobeNewswire) +7.60%
Oct-18-22 07:00AM	atai Life Sciences Announces Initiation of Phase 1 Proof-of-Concept Clinical Trial for Its Sol-gel Based Direct-to-Brain Drug Delivery Technology (GlobeNewswire)
Oct-13-22 09:21AM	IntelGenxs Collaboration with atai Life Sciences Culminates in the Initiation of First-in-Human Clinical Study of an Oral Thin Film Psychedelic Drug Candidate (GlobeNewswire)
Oct-12-22 07:00AM	atai Life Sciences Announces Positive Initial Results for Phase 1 Trial of KUR-101, an Oral Formulation of Mitragynine for OUD (GlobeNewswire)
Oct-05-22 07:00AM	atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of Buccal and IV VLS-01, a Synthetic Form of DMT (GlobeNewswire)
Oct-04-22 07:00AM	atai Life Sciences to Participate in October Investor Events & Host Virtual R&D Day (GlobeNewswire)
Sep-27-22 08:00AM	atai Life Sciences Announces Initiation of Phase 1 Trial for its MDMA Derivative, EMP-01 (GlobeNewswire) +7.96%
Sep-06-22 06:30PM	atai Life Sciences to Participate in September Investor Events (GlobeNewswire)
Aug-15-22 07:35AM	atai Life Sciences Reports Second Quarter 2022 Financial Results & Business Update (GlobeNewswire)
06:55AM	atai Life Sciences Secures Term Loan Facility for up to $175 Million from Hercules Capital (GlobeNewswire)
Aug-01-22 06:59AM	atai Life Sciences to Announce Second Quarter 2022 Financial Results and Business Update (GlobeNewswire) -8.03%
Jul-22-22 06:40AM	New Regulations for Psychedelics? Here's What Investors Need to Know (Motley Fool)
Jul-12-22 12:10PM	Cathie Wood Watch: Ark Buys Big Into Biotech (TheStreet.com)
Jun-30-22 06:59AM	atai Life Sciences Company Kures Therapeutics Appoints Dr. Chad Beyer as Chief Executive Officer (GlobeNewswire)
Jun-17-22 06:59AM	Stephen Bardin to Join atai Life Sciences as CFO Designate (GlobeNewswire)
Jun-16-22 05:59AM	atai Life Sciences to Participate in Upcoming June Healthcare Conferences (GlobeNewswire) -6.04%
Jun-15-22 10:21AM	Here's Why We're Not Too Worried About Atai Life Sciences' (NASDAQ:ATAI) Cash Burn Situation (Simply Wall St.)
May-16-22 06:55AM	atai Life Sciences Reports First Quarter 2022 Financial Results and Business Update (GlobeNewswire) +10.99%
May-06-22 11:20AM	Cathie Woods Latest Portfolio: 10 New Stock Picks in 2022 (Insider Monkey)
May-05-22 03:19PM	CORRECTION - atai Life Sciences to Announce First Quarter 2022 Financial Results and Business Update (GlobeNewswire) -8.45%
May-04-22 04:00AM	atai Life Sciences to Announce First-Quarter 2022 Financial Results (GlobeNewswire)
Apr-19-22 03:22PM	EXCLUSIVE: ATAI Life Sciences Deploys Decentralized Approach To Transform Mental Health Treatments (Benzinga)
12:26PM	atai Life Sciences to Participate in Upcoming April Investor Conference (GlobeNewswire)
Apr-13-22 10:00AM	Healthcare Breakthroughs: Atai, Nova Mentis, PolarityTE, and LIXTE; Biomed Leaders Report Latest Advances in Regenerative Tissue Technology, Psychedelics, and New Therapeutics for Autism, Mental Health and Cancers (GlobeNewswire) +5.49%
Mar-30-22 06:59AM	atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial Results, Reports on R&D Progress and Highlights Strategic Focus Areas of its Innovative Mental Health Platform (GlobeNewswire)
Mar-23-22 06:59AM	atai Life Sciences to Host Conference Call and Webcast to Discuss Results for the Fourth Quarter and Full Year 2021 and Corporate Update (GlobeNewswire) -7.03%
Mar-21-22 01:08PM	atai Life Sciences to Participate in Upcoming March Investor Conferences (GlobeNewswire) -6.55%
Feb-16-22 06:59AM	atai Impact Donates to the Multidisciplinary Association for Psychedelic Studies (MAPS) to Support Pioneering Work in Psychedelic Medicine (GlobeNewswire) +5.76%
Feb-15-22 06:59AM	atai Life Sciences to Participate in Upcoming February Investor Conference (GlobeNewswire) +5.17%
Jan-12-22 06:59AM	atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program (GlobeNewswire)
Jan-10-22 01:03PM	atai Life Sciences to Participate in Upcoming January Investor Conference (GlobeNewswire)
Dec-29-21 08:40AM	Implied Volatility Surging for ATAI Life Sciences (ATAI) Stock Options (Zacks)
Dec-23-21 06:48AM	The Zacks Analyst Blog Highlights: PSY, PSIL, Atai Life Sciences, COMPASS Pathways and Field Trip Health (Zacks)
Dec-22-21 01:43PM	3 Psychedelic Stocks to Play the Shroom Boom (Zacks) -6.12%
Dec-17-21 07:30AM	Armada Acquisition Corp. I to acquire Rezolve Mobile Engagement Platform in $2bn deal (GlobeNewswire) +5.41%
Dec-16-21 06:59AM	atai Impact Establishes the atai Fellowship Fund in Psychedelic Neuroscience with Massachusetts General Hospitals Center for the Neuroscience of Psychedelics (GlobeNewswire) +11.14%
Dec-15-21 04:19PM	Psychedelic Drug Firms Billionaire Backer Will Hold Onto Stake (Bloomberg) -31.94%
06:57AM	Apeiron and Other Key Shareholders of atai Life Sciences Reinforce Support by Entering into Extended, Voluntary Share Lock-up Agreements (GlobeNewswire)
Dec-14-21 07:30AM	atai Life Sciences Announces Successful Outcome of Phase 2a Biomarker Trial of RL-007 in Cognitive Impairment Associated with Schizophrenia (GlobeNewswire) -9.07%
Dec-13-21 06:59AM	atai Life Sciences Has Been Selected for Addition to the NASDAQ Biotechnology Index (GlobeNewswire)
Dec-09-21 10:30AM	atai Life Sciences launches TryptageniX to further expand atais robust intellectual property portfolio and strengthen atai's supply chain (GlobeNewswire) -5.10%
Dec-06-21 07:01AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Nov-29-21 07:00AM	atai Life Sciences Increases its Ownership Position in COMPASS Pathways (GlobeNewswire)
Nov-15-21 06:59AM	atai Life Sciences Reports Third Quarter 2021 Financial Results and Corporate Update (GlobeNewswire) -13.87%
Nov-08-21 08:30AM	atai Life Sciences to Host Conference Call and Webcast to Discuss Third Quarter 2021 Financial Results and Provide Business Update (GlobeNewswire)
Nov-05-21 04:30PM	atai Life Sciences to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Nov-02-21 04:43PM	This Psychedelics Stock Was Up More Than 20% Last Week, Outperforming Tesla, Nvidia and GameStop (Benzinga) +9.54%

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Berlin, Germany.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rao Srinivas	See Remarks	Apr 02 '24	Sale	1.85	61,640	114,034	113,360	Apr 04 06:11 PM
Kirpekar Sahil	Chief Business Officer	Apr 02 '24	Sale	1.85	35,801	66,232	64,199	Apr 04 06:11 PM
Johnson Anne Nagengast	Chief Financial Officer	Apr 02 '24	Sale	1.85	27,410	50,708	73,590	Apr 04 06:11 PM
Brand Florian	See Remarks	Nov 16 '23	Buy	1.16	20,000	23,120	130,000	Nov 20 09:17 AM
Brand Florian	See Remarks	Sep 13 '23	Buy	1.45	40,000	57,968	110,000	Sep 14 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ATAI

ATAI Life Sciences N.V.

Upgrade your FINVIZ experience